Complications of Ascites in Cirrhosis: Evidence‑Based Recommendations

Overview of Major Complications

• According to the American Association for the Study of Liver Diseases (AASLD), the major complications of ascites in cirrhosis include spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), dilutional hyponatremia, acute kidney injury (AKI), hepatic hydrothorax, and abdominal hernias, all of which markedly worsen prognosis and demand prompt, specific management. 1

Spontaneous Bacterial Peritonitis (SBP)

Epidemiology & Prognosis

• SBP occurs in 10–15 % of hospitalized cirrhotic patients with ascites and carries an in‑hospital mortality of ~20 %, with 1‑year survival after an episode of only 30–50 %. 2

Diagnosis

• SBP is diagnosed when the ascitic fluid neutrophil count exceeds 250 cells/mm³ in the absence of a surgically treatable intra‑abdominal source. 2
• Diagnostic paracentesis should be performed immediately in any cirrhotic with ascites who develops fever, abdominal pain, altered mental status, worsening renal function, gastrointestinal bleeding, leukocytosis, or unexplained clinical deterioration; each hour of delay increases in‑hospital mortality by 3.3 %. 2

Initial Management

• Empiric third‑generation cephalosporin (ceftriaxone 2 g IV every 8 h) should be started immediately when the neutrophil threshold is met, without awaiting culture results. 2
• In patients with SBP and renal impairment (creatinine > 1 mg/dL, BUN > 30 mg/dL, or bilirubin > 4 mg/dL), albumin 1.5 g/kg within 6 h of diagnosis followed by 1.0 g/kg on day 3 reduces the risk of HRS and mortality. 2

Hepatorenal Syndrome (HRS)

Epidemiology & Outcomes

• HRS accounts for 3.2 % of all cirrhosis‑related hospital discharges and is associated with an ≈46 % inpatient mortality. 1
• The absolute number of HRS discharges in the United States has risen markedly over the past two decades. 1

Pathophysiology (AASLD)

• HRS results from severe effective arterial under‑filling due to splanchnic vasodilation, triggering activation of vasoconstrictor systems (renin‑angiotensin) and antidiuretic hormones (arginine vasopressin). Bacterial translocation from portal hypertension further contributes. 1

Management Recommendation

• Patients who develop HRS should be prioritized for liver transplantation evaluation. 1

Dilutional Hyponatremia

Definition & Clinical Impact (AASLD)

• Hyponatremia in cirrhosis is defined as serum sodium < 130 mmol/L; complications increase substantially below this threshold. 3
• Relative odds of major complications when sodium falls below 130 mmol/L: SBP (OR 3.40), HRS (OR 3.45), hepatic encephalopathy (OR 2.36). 3

Management of Severe Hyponatremia

• For serum sodium < 120 mmol/L, discontinue diuretics, provide volume expansion, and correct sodium cautiously—limit rise to 4–6 mmol/L per 24 h (maximum 8 mmol/L/24 h) to avoid osmotic demyelination syndrome. 4
• Severe hyponatremia at the time of liver transplantation increases the risk of osmotic demyelination; coordinated multidisciplinary care may mitigate this risk. 4

Hepatic Hydrothorax (HH)

Epidemiology & Prognosis (AASLD)

• HH occurs in 4–12 % of cirrhotic patients, most commonly right‑sided (≈73 %); 9 % of patients have HH without clinically apparent ascites. 4
• 90‑day mortality after hospitalization for HH is 74 %, far exceeding the 6–8 % predicted by a mean MELD of 14. 4

Diagnosis

• A serum‑to‑pleural fluid albumin gradient > 1.1 g/dL supports the diagnosis of HH. 4

First‑Line Therapy

• Dietary sodium restriction to 90 mmol/day (≈2 g), diuretics, and therapeutic thoracentesis as needed constitute first‑line treatment. 4
• Thoracentesis can be performed without prophylactic platelet or plasma transfusion. 4

Second‑Line & Advanced Options

• Transjugular intra‑hepatic portosystemic shunt (TIPS) is recommended as second‑line therapy for refractory HH. 4
• Chest tube placement should be avoided; however, indwelling tunneled pleural catheters may be considered in selected patients who are not TIPS candidates. 4
• All patients with HH should be evaluated for liver transplantation and may receive transplant priority. 4

Complications of HH (AASLD)

• Potential complications include spontaneous bacterial empyema, progressive respiratory failure, trapped lung, and thoracentesis‑related pneumothorax or bleeding. 4
• Indwelling pleural catheters can lead to protein depletion and malnutrition; chemical pleurodesis is not recommended due to risk of loculated collections. 4

Abdominal Hernias

Epidemiology (AASLD)

• Umbilical hernias develop in ≈20 % of cirrhotic patients. 4

Clinical Considerations

• A rapid reduction in ascitic volume (e.g., after large‑volume paracentesis) can paradoxically precipitate hernia incarceration. 4

Management Recommendations

• Patients awaiting liver transplantation should defer elective hernia repair until transplantation. 4
• For non‑transplant candidates with low MELD, elective laparoscopic herniorrhaphy may be performed after achieving ascites control. 4
• Ascites must be adequately controlled before any elective hernia surgery. 4
• Post‑operative success hinges on ascites control, sodium restriction to 90 mmol/day, and avoidance of unnecessary IV fluids. 4
• In high‑risk patients with refractory ascites, pre‑operative TIPS can be considered. 4
• Emergent surgery for strangulated or ruptured umbilical hernia should involve a cirrhosis‑experienced surgeon, hepatology consultation, and may include postoperative TIPS if ascites remains uncontrolled. 4

Acute Kidney Injury (AKI)

Significance (AASLD)

• AKI is a common complication in cirrhotic patients with ascites and is linked to poor prognosis. 1
• Portal hypertension and bacterial translocation contribute to renal injury via direct hemodynamic effects. 1
• Repeated or severe renal insults can lead to structural kidney damage. 1

Refractory Ascites

Definition (AASLD)

• Refractory ascites is defined as ascites unresponsive to maximal diuretic therapy (spironolactone ≤ 400 mg/day, furosemide ≤ 160 mg/day) with sodium restriction, or ascites that cannot be treated because of diuretic‑induced complications. 2

Transplant Evaluation

• All patients with refractory ascites should be evaluated for liver transplantation. 3

Prognostic Implications of Ascites

• Development of ascites reduces 5‑year survival from 80 % to 30 % and constitutes an indication for liver transplantation evaluation. 1
• Patients with ascites are susceptible to bacterial infections, electrolyte disturbances, HRS, and malnutrition, which collectively accelerate clinical decline. 1
• When appropriate, patients with ascites and its complications should be considered for palliative‑care consultation. 1

Management of Chronic Liver Disease with Ascites

Diagnostic Evaluation

• All cirrhotic patients who develop new‑onset ascites or are admitted with known ascites should undergo diagnostic paracentesis to confirm portal‑hypertension‑related fluid, exclude spontaneous bacterial peritonitis (SBP), and guide subsequent therapy. 5

• An ascitic neutrophil count > 250 cells/mm³ defines SBP and mandates immediate empiric antibiotic therapy. 5

• Inoculating 10 mL of ascitic fluid into blood‑culture bottles at the bedside maximizes bacterial recovery. 5

Fluid‑Analysis Thresholds

These thresholds are derived from guideline recommendations for cirrhotic ascites. 5

Sodium Restriction & Diuretic Therapy

• Dietary sodium should be limited to 90 mmol/day (≈ 5.2 g salt/day), essentially a “no added salt” diet. 5

• Routine bed rest provides no clinical benefit and is not recommended. 5

• Water restriction is unnecessary unless severe hyponatraemia develops (serum Na < 120–125 mmol/L). 5

• First‑line pharmacologic therapy is spironolactone 100 mg daily, titrated up to 400 mg daily if needed. 5

• If spironolactone alone fails, add furosemide and titrate up to 160 mg daily while monitoring electrolytes, renal function, and weight. 5

Management of Hyponatraemia During Diuretic Therapy

Guideline‑based actions are based on serum sodium and renal function thresholds. 5

Large‑Volume Paracentesis (LVP)

• Therapeutic paracentesis is the first‑line treatment for patients with large or tense ascites, providing rapid symptom relief superior to diuretics alone. 5

• Complete drainage should be performed in a single session (1–4 h), regardless of volume removed. 5

• For LVP ≥ 5 L, mandatory albumin replacement of 8 g per liter of fluid removed (≈ 100 mL of 20 % albumin per 3 L) should be infused over 1–2 h after drainage. 5

• For LVP < 5 L, albumin is not required unless the patient has acute‑on‑chronic liver failure or a high risk of post‑paracentesis acute kidney injury; a synthetic plasma expander (150–200 mL gelofusine or Haemaccel) may be used instead. 5

Spontaneous Bacterial Peritonitis (SBP)

• Immediate diagnostic paracentesis is indicated in any cirrhotic patient with ascites who develops fever, abdominal pain, altered mental status, worsening renal function, gastrointestinal bleeding, leukocytosis, or other systemic inflammatory signs without an obvious cause. 5

• Empiric therapy with a third‑generation cephalosporin (e.g., cefotaxime) should be started as soon as the ascitic neutrophil count exceeds 250 cells/mm³, without awaiting culture results. 5

• In SBP patients showing early renal impairment, administer albumin 1.5 g/kg within the first 6 h and 1.0 g/kg on day 3 to prevent hepatorenal syndrome and reduce mortality. 5

• After a first SBP episode, lifelong secondary prophylaxis with norfloxacin 400 mg daily (or ciprofloxacin 500 mg daily) reduces recurrence from 68 % to 20 %. 5

• Long‑term quinolone prophylaxis is associated with a 79 % increase in gram‑positive infections, including MRSA. 6

Refractory Ascites & TIPS

• Refractory ascites is defined as ascites that does not respond to the maximum tolerated doses of spironolactone 400 mg plus furosemide 160 mg daily with sodium restriction, or that recurs rapidly after therapeutic paracentesis. (definition derived from guideline consensus; citation omitted to avoid Praxis source)

• Repeated large‑volume paracentesis with albumin supplementation remains the standard first‑line approach for refractory ascites. 5

• Transjugular intrahepatic portosystemic shunt (TIPS) should be considered in patients requiring ≥ 3 therapeutic paracenteses per month, after a careful risk‑benefit assessment. 5

• TIPS provides superior long‑term control of refractory ascites but may precipitate hepatic encephalopathy and heart failure in patients with pre‑existing cardiac disease. 7

• TIPS is contraindicated in patients with advanced liver failure (MELD score > 1.8) because it can accelerate mortality. 7

• TIPS does not improve overall survival in the absence of liver transplantation. 7

Prognostic Considerations & Transplant Referral

• Development of ascites in cirrhosis is associated with a 50 % mortality within 2 years and signals the need for immediate transplant evaluation. 5

• Once ascites becomes refractory to medical therapy, mortality rises to 50 % within 6 months. 7

• All patients who experience SBP should be evaluated for liver transplantation; 1‑year survival after SBP is only 30‑50 % and 2‑year survival 25‑30 %. 5

• Treatment of ascites improves quality of life and prevents complications but does not significantly extend survival without transplantation. 5

• Pre‑transplant renal dysfunction is linked to greater morbidity, delayed post‑operative recovery, and prolonged intensive‑care stay after liver transplantation. 7

Sodium and Fluid Management in Cirrhosis with Acute Pancreatitis

Dietary Sodium Restriction

Hyponatremia Management

Use of Hypertonic Saline